SBIR/STTR Research Award
Microfluidic Magnetic Anisotropic Array for High-throughput Isolation of Extracellular Vesicles and Exosomes
Award amount
$255,980Program and phase
SBIR · Phase IAward year
2018Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- Clara Biotech, Inc.
- Proposal award date
- 2018-04-11
- Contract end date
- 2019-11-10
- UEI
- N1BRM2P2RT48
- Solicitation number
- PA17-302
- Topic code
- 396
Research abstract
ABSTRACT
Tumor derived circulating exosomes has been emerging in fundamental cancer researchclinical diagnosis
and monitoring of treatment responsesHoweverthe specific preparation of enricheddistinct exosome
populations is still challengingCurrentlythe most common procedure for purifying exosomes involves a series
of high speed ultracentrifugation steps in order to remove cell debris and pellet exosomesCommercially
available exosome isolation kits still need a benchtop centrifuge before the chemical precipitation of exosomal
molecular contentsThe isolation protocols are tedious and time consuminghwith relatively low yield
and recovery purityIn order to substantially improve isolation performance and throughputClara
Diagnostics Incproposes to develop a microfluidic based isolation platform as a research tool for automatedhigh specific and high throughput processing of tumor exosomes and subtypes from a wide variety of biofluidsin response to NIH PASBIR Phase I Funding OpportunityCurrentlythere is no any microfluidic based
exosome isolation platform commercially availablealthough microfluidic technology has proved unmatched
capability for exosome processing and molecular profilingClara Diagnostics Incaims to fulfill this gap by
developing the first microdevice product which enables the automatedhigh throughput and continuous
processing ofsamples on demandThe implementation of magnetic anisotropic oscillation inchannel
microfluidic device enables ultra fast mixing of beads with biofluids while using high flow ratesThe single
channel processing speed isL min with a throughput ofchannelsNote that conventional
ultracentrifugation or differential centrifugation processes total blood plasma volume ofmL inh orsamples per runOur proposed platform can processsamples with total processing volume ofmL inhwhich isfold increaseTogether with the high throughput operation and high specificity to tumorexosomes and subtypeswe will deliver a genericenabling platform for preparing enricheddistinct exosome
subpopulations from a wide variety of biofluidssuch as blood serumplasmaurinesalivacell culture
mediummalignant ascitesand milkThis product as a research tool can process sample volumes fromchannels in microliter for on chip analysis to milliliter preparation for variable downstream benchtop
measurements and therapeutic applicationse gmass spectrometryPCRand sequencingand delivery
carrierIn strong contrast to current commercial exosome isolation kitsthe proposed microfluidic platform will
present a new generation of product that offers unmatched sample processing capabilities for exosome
research and immensely accelerates cancer research and clinical development of liquid biopsy RELEVANCE TO PUBLIC HEALTH
The utility of exosomesparticularly tumor derived circulating exosomesis pressingly necessary to fundamental
cancer researchclinical diagnosis and monitoring of treatment responsesClara Diagnostic Inchas strived to
deliver a robustness and ease of use research tool for efficient exosome isolation from variable body fluidsultimately advancing exosomes cancer research
Technology keywords
Not reported
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- SBIR PHASE II - TOPIC 396 - IMAGING FOR CANCER IMMUNOTHERAPIES
- Molecular, cancer-specific, intraoperative imaging of breast surgical margin assessment
- Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer
- Development of a PSMA x PSMA x CD3 trivalent, bispecific T-cell engaging antibody to treat Castration Resistant Prostate Carcinoma